Patients in the United States who take thyroid medication may want to check their medicine bottles after Vitruvias Therapeutics, Inc. issued a voluntary nationwide recall of one lot of its Thyroid Tablets, USP 30 mg
This recall concerns Lot 504950, which was tested and confirmed to possibly be superpotent, meaning it may have higher thyroid hormone quantities than intended by the manufacturer. The news was published by the U.S. Food and Drug Administration (FDA) on August 24, 2026, after the company announced the action on August 21.
Which Thyroid Tablets Are Being Recalled?
The recall involves a single lot of Vitaivus Therapeutics Thyroid Tablets USP, 30 mg
Patients and pharmacies can use the following product details to identify the affected medication.
Product: Thyroid Tablets, USP 30 mg
NDC: 69680-166-00
Lot number: 504950
Expiration date: September 30, 2026
Units released: 3,655
Units sold: 1,955
The recalled product was distributed nationwide to Vitruvias Therapeutics’ direct accounts in the United States during the period indicated below.
Why Was the Medication Recalled?
The issue is related to potency.
Thyroid Tablets, USP are used to treat hypothyroidism, a condition in which the body does not produce enough thyroid hormone. The medication is a natural preparation derived from porcine thyroid glands and contains the thyroid hormones levothyroxine (T4) and liothyronine (T3).
If the tablets contain more thyroid hormone than intended, patients could receive an excessive dose. The FDA says this can potentially lead to hyperthyroidism, or an overactive thyroid.
Possible symptoms include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heartbeat and abnormal heart rhythms.
FDA Raises Recall to Class I
The recall has since been classified by the FDA as a Class I recall, the agency's highest-risk recall category. The classification indicates that exposure to the recalled product could reasonably be expected to cause serious adverse health consequences or death. The classification is based on the potential risk associated with the recalled lot; it does not mean that every patient who used the product will experience serious harm
Who Could Face Greater Risk?
The FDA specifically notes that older adults, pregnant women and infants may face greater risks from excessive thyroid hormone exposure, particularly when the exposure continues over an extended period.
For older adults, excessive thyroid hormone can create additional concerns involving cardiovascular health. During pregnancy, overtreatment of hypothyroidism has been associated with complications including premature delivery and low birth weight. In infants, excessive thyroid hormone exposure may negatively affect growth and development.
These risks do not mean that everyone who used the recalled lot will experience complications. Vitruvias Therapeutics said it had not received reports of adverse events known to be related to the recall as of its announcement.
What Should Patients Do?
Patients who have Thyroid Tablets, USP 30 mg from Lot 504950 should contact their healthcare provider for guidance before making any changes to their treatment.
The FDA and Vitruvias Therapeutics advise patients not to discontinue the medication without first consulting their healthcare provider. A healthcare professional can determine whether the medication should be replaced and, if appropriate, provide a replacement prescription.
Patients who believe they have experienced a problem associated with the medication should contact their healthcare provider. The FDA also encourages reporting adverse reactions or quality concerns through its MedWatch reporting program.
Consumers with questions about the recall can contact Vitruvias Therapeutics at safety@vitruvias.com or (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. CT.
A Reminder About Checking Medication Recalls
A drug recall usually involves a certain lot or batch of a particular medication manufactured within a defined time frame. It is highly essential for patients to confirm this information with the label on their medication bottles to ensure that they are not using a recalled product. In this case, the recall involves Vitaivus Therapeutics Thyroid tablets USP 30 mg, lot 504950. Vitruvias has no reason to believe that they have distributed this medication in any other dosage strengths.
The Vitruvias product warning is an excellent reminder of the importance of clinical potency testing and quality control in pharmaceutical manufacturing, especially for life-saving medications. Even minor changes in a medication’s potency can significantly affect patient health outcomes.
Frequently Asked Questions
1. Which brand of Vitruvias thyroid medication has been recalled?
Thyroid Tablets, USP 30 mg, lot 504950, NDC 69680-166-00, expiry 9/30/26, have been recalled.
2. Why has Vitruvias recalled the thyroid tablets?
Vitruvias has recalled the product due to the detection of super-potency.
3. What symptoms might develop if the tablets are taken?
Hyperthyroidism features include racing heart palpitations, feeling anxious, feeling too hot or too cold, weak muscles, weight loss, high blood pressure, and chest pain.
4. Do patients need to stop taking the medication?
Patients taking Thyroid Tablets, USP 30 mg from recalled Lot 504950 should contact their healthcare provider before making changes to their treatment. The FDA advises patients not to discontinue the medication without professional guidance. A healthcare provider can determine whether a replacement prescription is appropriate.
5. Had Vitruvias received any adverse event reports after the product launch?
As of the date of the recall, Vitruvias has not received any adverse event reports known to be associated with the product.
.webp)
